Doxycycline restrains glia and confers neuroprotection in a 6‐OHDA Parkinson model
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Neuron–glia interactions play a key role in maintaining and regulating the central nervous system. Glial cells are implicated in the function of dopamine neurons and regulate their survival and resistance to injury. Parkinson's disease is characterized by the loss of dopamine neurons in the substantia nigra pars compacta, decreased striatal dopamine levels and consequent onset of extrapyramidal motor dysfunction. Parkinson's disease is a common chronic, neurodegenerative disorder with no effective protective treatment. In the 6‐OHDA mouse model of Parkinson's disease, doxycycline administered at a dose that both induces/represses conditional transgene expression in the tetracycline system, mitigates the loss of dopaminergic neurons in the substantia nigra compacta and nerve terminals in the striatum. This protective effect was associated with: (1) a reduction of microglia in normal mice as a result of doxycycline administration per se; (2) a decrease in the astrocyte and microglia response to the neurotoxin 6‐OHDA in the globus pallidus and substantia nigra compacta, and (3) the astrocyte reaction in the striatum. Our results suggest that doxycycline blocks 6‐OHDA neurotoxicity in vivo by inhibiting microglial and astrocyte expression. This action of doxycycline in nigrostriatal dopaminergic neuron protection is consistent with a role of glial cells in Parkinson's disease neurodegeneration. The neuroprotective effect of doxycycline may be useful in preventing or slowing the progression of Parkinson's disease and other neurodegenerative diseases linked to glia function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676 · cited 1×
“Microglia embody the main component of the brain immune system (Hanisch and Kettenmann, 2007; Soulet and Rivest, 2008).”
BackgroundTranscriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 2×
“Furthermore, doxycycline is one of the tetracyclines most commonly used in conditional transgene expression systems in lab animals, being added either to the drinking water or chow (Furth et al., 1994; Gossen et al., 1995; Lee et al., 2009; Mansuy et al., 1998; Redfern et al., 1999; for review see Berkhout et al., 200…”
BackgroundIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 2×
“Microglia are activated before dopaminergic neurons degenerate and an increased activity of microglia in the brain of Parkinson’s patients has been detected (Gerhard et al., 2006; JacksonLewis et al., 1995).”
BackgroundWu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 6×
“Microglial activation is a prominent feature of Parkinson’s disease and also induced by lesioning dopaminergic substantia nigra pars compacta neurons (Sanchez-Pernaute et al., 2004; Vila et al., 2001; Walker and Lue, 2005; Wu et al., 2002).”
BackgroundInfluentialLiu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 2×
“Mitigation of SNc dopaminergic neuronal loss does not always correlate with sparing of the corresponding striatal nerve fibers (Liberatore et al., 1999a,b), which are essential for maintaining dopaminergic neurotransmission.”
BackgroundTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 6×
“…effect of minocycline has been shown to be mediated by inhibition of microglial activation (Amin et al., 1996; Festoff et al., 2006; He et al., 2001; Tikka and Koistinaho, 2001; Yrjanheikki et al., 1998, 1999), an anti-inflammatory property completely distinct from its antimicrobial action.”
BackgroundInfluentialHenry, C. J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M. T., Sheridan, J. F., & Godbout, J. P. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-15 · Cited by 678
Trophic Interactions Between Astroglial Cells and Hippocampal Neurons in Culture
Banker, G. A. (1980) · Science · doi:10.1126/science.7403847 · Cited by 674
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
The role of glial cells in Parkinsonʼs disease
Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00009 · Cited by 326
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · cited 2×
“of Parkinson’s disease and in experimental lesioning of dopaminergic SNc neurons (Akiyama and McGeer, 1989; Czlonkowska et al., 1996; He et al., 2000; Kim et al., 2009; Sanchez-Pernaute et al., 2004; Vila et al., 2001; Walker and Lue, 2005; Wu et al., 2002).”
BackgroundDeleterious Effects of Minocycline in Animal Models of Parkinson’s Disease and Huntington’s Disease
Diguet, E., Fernagut, P., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., & Tison, F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03372.x · Cited by 189
Minocycline Enhances MPTP Toxicity to Dopaminergic Neurons
Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10709 · Cited by 158
Clinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157 · cited 2×
“While there are limitations in the translation of results from rodents to humans, these findings nevertheless hold the prospect that the readily available, inexpensive and in terms of risk, safe drug doxycycline, could be used for the treatment of human neurodegenerative diseases (Blum et al., 2004; Domercq and Matute…”
BackgroundYim, C. W., Flynn, N. M., & Fitzgerald, F. T. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.2.347 · Cited by 133
Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Thomas, M., & Le, W. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453162 · Cited by 114 · cited 1×
“The tetracycline-derivative doxycycline (a-6 deoxy5-hydroxytetracycline) has been shown to be neuroprotective in in vitro and in vivo models of neurodegenerative diseases (Du et al., 2001; Kim and Suh, 2009; Purisai et al., 2007; Thomas and Le, 2004; Wang et al., 2003).”
BackgroundImaging of microglia in patients with neurodegenerative disorders
Politis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00096 · Cited by 111
Cho, Y., Son, H. J., Kim, E.-M., Choi, J. H., Kim, S. T., Ji, I. J., Choi, D. H., Joh, T. H., Kim, Y. S., & Hwang, O. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9078-1 · Cited by 85 · cited 1×
“Cho et al. (2009) and Wang et al. (2009) recently presented evidence of in vitro and in vivo doxycycline neuroprotection of the nigral dopaminergic neurons following either 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine (MPTP)-induced or lipopoly-saccharide (LPS) treatment in mice.”
Background
Cited by
Practical considerations for choosing a mouse model of Alzheimer’s disease
Jankowsky, J. L., & Zheng, H. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0231-7 · Cited by 449
Doxycycline Suppresses Microglial Activation by Inhibiting the P38 MAPK and NF-KB Signaling Pathways
Santa-Cecília, F. V., Socias, B., Ouidja, M. O., Sepulveda-Diaz, J. E., Acuña, L., Silva, R. L., Michel, P. P., Del-Bel, E., Cunha, T. M., & Raisman-Vozari, R. (2016) · Neurotoxicity Research · doi:10.1007/s12640-015-9592-2 · Cited by 165
“We previously demonstrated in a 6-OHDA mouse model of PD that orally ingested or subcutaneously injected doxycycline protects dopaminergic neurons (Lazzarini et al. 2013).”
BackgroundResultReglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Self-citationGonzález-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., et al. (2017) · Scientific Reports · doi:10.1038/srep41755 · Cited by 119
Self-citationVaresi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Metadata
- Authors
- Lazzarini, M., Martin, S., Mitkovski, M., Vozari, R. R., Stühmer, W., & Bel, E. D.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2013-04-17
- Volume
- 61
- Issue
- 7
- Pages
- 1084-1100
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2132435801
- Cited by
- 117
- References
- 20
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.